特布他林辅助阿奇霉素序贯治疗小儿肺炎的疗效及其对患儿气道炎症因子的影响

目的：观察特布他林辅助阿奇霉素序贯治疗小儿肺炎的疗效，并探讨其对患儿气道炎症因子的影响。方法收集我院儿科2014年7月至2015年7月收治的100例肺炎患儿，依据掷硬币法随机数表法分为对照组和观察组，每组50例。对照组患儿采用阿奇霉素序贯治疗，观察组在对照组基础上辅助特布他林治疗，两组均持续性治疗14 d，比较两组患儿治疗前后的炎症因子[超敏-C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)]水平、体征与症状消失时间、疗效、不良反应和住院时间。结果治疗后，观察组患儿的hs-CRP、TNF-α、IL-6水平分别为(4.59±1.12) mg/L、(18.34±5.06) mg/L和(25.20±7.23) mg/L，均低于对照组的(11.65±3.52) mg/L、(26.53±5.57) mg/L和(36.84±7.59) mg/L，差异均有统计学意义(P<0.05)；观察组患儿的退热时间、止咳时间、肺部啰音消失时间分别为(1.34±0.32) d、(4.28±1.02) d和(5.03±1.17) d ，均优于对照组的(2.25±0.57) d、(5.76±1.35) d和(7.84±1.46) d，差异均有统计学意义(P>0.05)；观察组患儿总有效率为96.00%(48/50)，高于对照组的84.00%(42/50)，差异有统计学意义(P>0.05)；观察组患儿的住院时间为(7.54±1.30) d，低于对照组的(9.84±1.78) d，差异有统计学意义(P<0.05)；治疗期间两组患儿不良反应相当，差异无统计学意义(P>0.05)。结论特布他林辅助阿奇霉素序贯治疗小儿肺炎的临床效果确切，其能够显著降低气道炎症因子水平，缓解机体炎症反应，促进恢复。

Clinical efficacy of terbutaline-assisted azithromycin sequential therapy in treatment of pediatric pneumonia and its effect on airway inflammatory factors

Objective To observe the clinical efficacy of terbutaline-assisted azithromycin sequential therapy in treatment of pediatric pneumonia, and to explore its effect on airway inflammatory factors. Methods A total of 100 children with pneumonia in Department of Paediatrics in our hospital from July 2014 to July 2015 were analyzed. Ac-cording to the coin tossing random number table, the patients were divided into control group and observation group, with 50 cases in each group. The control group was treated with azithromycin sequential therapy, and the observation group applied terbutaline based on the control group, continuously for 14 days. The inflammatory factors such as high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-α(TNF-α), interleukin-6 (IL-6), signs and symp-toms disappear time, curative effect and adverse reaction, the length of stay were compared between the two groups. Results After treatment, the levels of hs-CRP, TNF-α, IL-6 in observation group were respectively (4.59±1.12) mg/L, (18.34±5.06) mg/L, (25.20±7.23) mg/L,which were significantly lower than those in control group of (11.65±3.52) mg/L, (26.53 ± 5.57) mg/L, (36.84 ± 7.59) mg/L, and the differences were statistically significant (P<0.05). The fever clearance time, the disappearance time of cough and pulmonary rales in observation group were respectively (1.34±0.32) d, (4.28± 1.02) d, (5.03 ± 1.17) d, which were better than those in control group of (2.25 ± 0.57) g, (5.76 ± 1.35) d, (7.84 ± 1.46) d, and the differences were statistically significant (P<0.05). The total effective rate 96.00%(48/50) in observation group was significantly higher than that in control group 84.00% (42/50), and the difference was statistically significant (P<0.05). The length of hospital stay (7.54 ± 1.30) d in observation group was significantly lower than that in control group (9.84±1.78) d, and the difference was statistically significant (P<0.05). There were no statistically significant differences in adverse reaction during the treatment between the two groups (P>0.05). Conclusion Terbutaline-assisted azithromy-cin sequential therapy in treatment of infantile pneumonia has significant effect, which can significantly reduce airway inflammation factor levels, ease the body's inflammatory response, and promote the recovery.